FDA Closes Inspection of Alvotech Facility, Clearing Key Hurdle
ALVO is trading near its 52-week low of $2.94 (8.2% above the low).
Summary
The FDA has successfully closed its inspection of Alvotech's manufacturing facility, a critical step that removes a major regulatory overhang. This follows a series of recent capital raises totaling over $165 million and the resubmission of BLAs for AVT05 and AVT06 in June. The closure signals that the facility meets FDA standards, potentially accelerating approval timelines for its biosimilar pipeline. With a market cap of $1.2 billion and shares at $3.18, the news directly addresses a key risk that has weighed on the stock. The next catalyst will be the FDA's decision on the pending BLAs, though no specific date has been set.
At the time of this announcement, ALVO was trading at $3.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.94 to $9.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.